COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study

Abstract Background Coronavirus disease 2019 (COVID-19) vaccine has played a major role in ending the pandemic. However, little is known about the influence of COVID-19 vaccine on the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). Objectives The goal of this study is...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yunfei Qian, Zhuxian Zhu, Yin-Yuan Mo, Ziqiang Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-09-01
Edice:	Infectious Agents and Cancer
Témata:	COVID-19 vaccination Immune checkpoint inhibitor (ICI) Non-small cell lung cancer (NSCLC) Progression-free survival (PFS) Overall survival (OS)
On-line přístup:	https://doi.org/10.1186/s13027-023-00526-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!